Seven months after the start of the health crisis, French pharmaceutical companies are stepping up to the plate.
The epidemic has highlighted the urgency of strengthening the health independence of France and Europe.
The supply pressures on many drugs (anesthetics, analgesics, antibiotics, etc.) have made the general public aware of the heavy dependence of Western countries on India and China, where more three quarters of the active ingredients (molecules containing the therapeutic effect) used in our medicines.
Read also:
Coronavirus: relocating production, a challenge for the pharmaceutical industry
As part of the recovery plan, Emmanuel Macron has made health independence a priority and called on drug manufacturers to take up the challenge of relocation to the Old Continent.
Not all drugs can be 100% manufactured in Europe.
The thirty-five basic molecules of anticancer drugs come, in fact, from three Chinese manufacturers.
Still, 15 billion will be spent by
This article is for subscribers only.
You have 89% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Enter your email
Already subscribed?
Log in
